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Abstract
We report unbiased metagenomic detection of chikungunya virus (CHIKV), Ebola virus (EBOV), and hepatitis C virus
(HCV) from four human blood samples by MinION nanopore sequencing coupled to a newly developed,
web-based pipeline for real-time bioinformatics analysis on a computational server or laptop (MetaPORE). At
titers ranging from 107–108 copies per milliliter, reads to EBOV from two patients with acute hemorrhagic
fever and CHIKV from an asymptomatic blood donor were detected within 4 to 10 min of data acquisition,
while lower titer HCV virus (1 × 105 copies per milliliter) was detected within 40 min. Analysis of mapped nanopore
reads alone, despite an average individual error rate of 24 % (range 8–49 %), permitted identification of the correct
viral strain in all four isolates, and 90 % of the genome of CHIKV was recovered with 97–99 % accuracy. Using
nanopore sequencing, metagenomic detection of viral pathogens directly from clinical samples was performed
within an unprecedented <6 hr sample-to-answer turnaround time, and in a timeframe amenable to actionable
clinical and public health diagnostics.
Background
Acute febrile illness has a broad differential diagnosis
and can be caused by a variety of pathogens. Metage-
nomic next-generation sequencing (NGS) is particularly
attractive for diagnosis and public health surveillance
of febrile illness because the approach can broadly de-
tect viruses, bacteria, and parasites in clinical samples
by uniquely identifying sequence data [1, 2]. Although
currently limited by sample-to-answer turnaround
times typically exceeding 20 hr (Fig. 1a), we and others
have reported that unbiased pathogen detection using
metagenomic NGS can generate actionable results in
timeframes relevant to clinical diagnostics [3–6] and
public health [7, 8]. However, timely analysis using
second-generation platforms such as Illumina and
Ion Torrent has been hampered by the need to wait
until a sufficient read length has been achieved for
diagnostic pathogen identification, as sequence reads
for these platforms are generated in parallel and not
in series.
Nanopore sequencing is a third-generation sequen-
cing technology that has two key advantages over
second-generation technologies – longer reads and
the ability to perform real-time sequence analysis. To
date, the longer nanopore reads have enabled scaf-
folding of prokaryotic and eukaryotic genomes and
sequencing of bacterial and viral cultured isolates [9–13],
but the platform’s capacity for real-time metagenomic
analysis of primary clinical samples has not yet been
leveraged. As of mid-2015, the MinION nanopore se-
quencer is capable of producing at least 100,000 se-
quences with an average read length of 5 kb, in total
producing up to 1 Gb of sequence in 24 hr on one
flow cell [14]. Here we present nanopore sequencing
for metagenomic detection of viral pathogens from
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clinical samples with a sample-to-answer turnaround
time of under 6 hr (Fig. 1a). We also present Meta-
PORE, a real-time web-based sequence analysis and
visualization tool for pathogen identification from
nanopore data (Fig. 1b).
Methods
Ethics statement
The chikungunya virus (CHIKV) plasma sample was col-
lected from a donor from Puerto Rico, who provided
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Fig. 1 Metagenomic sequencing workflow for MinION nanopore sequencing compared to Illumina MiSeq sequencing. a Overall workflow. b Steps in
the MetaPORE real-time analysis pipeline. The turnaround time for sample-to-detection nanopore sequencing, defined here as the cumulative time
taken for nucleic acid extraction, reverse transcription, library preparation, sequencing, MetaPORE bioinformatics analysis, and pathogen detection, was
under 6 hr, while Illumina sequencing took over 20 hr. The time differential is accounted for by increased times for library quantitation, sequencing,
and bioinformatics analysis with the Illumina protocol. *Assumes a 12-hr 50-bp single-end MiSeq run of ~12–15 million reads, with 50 bp the minimum
estimated read length needed for accurate pathogen identification. **Denotes estimated average SURPI bioinformatics analysis run length for MiSeq
data [19]. The stopwatch is depicted as a 12-hr clock
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clinical metadata in medical research [15]. For the Ebola
virus (EBOV) samples, patients provided oral consent
for collection and analysis of their blood, as was the case
for previous outbreaks [16, 17]. Consent was obtained
either at the homes of patients or in hospital isolation
wards by a team that included staff members of the
Ministry of Health in the Democratic Republic of the
Congo (DRC). The hepatitis C virus (HCV) sample was
a banked aliquot from a patient with known hepatitis C
infection at the University of California, San Francisco
(UCSF), and sequence analysis was performed under a
waiver of consent granted by the UCSF Institutional
Review Board.
MAP program
Since July 2014, our lab has participated in the MinION
Access Program (MAP), an early access program for
beta users of the Oxford Nanopore MinION. Program
participants receive free flow cells and library prepar-
ation kits for testing and validation of new protocols and
applications on the MinION platform. During our time
in the MAP program, we have seen significant progress
in sequencing yield, although the quality of flow cells
has varied considerably and individual read error rates
remain high (Table 1).
Nucleic acid extraction
Frozen surplus plasma samples were collected during
the peak weeks of the 2014 CHIKV outbreak in Puerto
Rico from blood donors [15], and were de-identified
prior to inclusion in the study. Total nucleic acid was
extracted from 400 μL of a CHIKV-positive plasma sam-
ple (Chik1) inactivated in a 1:3 ratio of TRIzol LS (Life
Technologies, Carlsbad, CA, USA) at the American Red
Cross prior to shipping to UCSF. The Direct-zol RNA
MiniPrep Kit (Zymo Research, Irvine, CA, USA) was
used for nucleic acid extraction, including on-column
treatment with Turbo DNAse (Life Technologies) for
30 min at 37 °C to deplete human host genomic DNA.
For the EBOV samples, total nucleic acid was extracted
using the QIAamp Viral RNA kit (Qiagen, Valencia, CA,
USA) from 140 μL of whole blood from two patients with
suspected Ebola hemorrhagic fever during a 2014 out-
break in the DRC (Ebola1 and Ebola2). RNA was ex-
tracted at Institut National de Recherche Biomédicale in
Kinshasa, DRC, preserved using RNAstable (Biomatrica,
San Diego, CA, USA), and shipped at room temperature
to UCSF. Upon receipt, the extracted RNA sample was
treated with 1 μL Turbo DNase (Life Technologies),
followed by cleanup using the Direct-zol RNA MiniPrep
Kit (Zymo Research).
For the HCV sample, an HCV-positive serum sample
at a titer of 1.6 × 107 copies/mL (HepC1) was diluted to
1 × 105 copies/mL using pooled negative serum. Total
nucleic acid was then extracted from 400 μL of serum
using the EZ1 Viral RNA kit, followed by treatment with
Turbo DNase for 30 min at 37 °C and cleanup using the
RNA Clean and Concentrator Kit (Zymo Research).
Molecular confirmation of viral infection
A previously reported TaqMan quantitative reverse-
transcription polymerase chain reaction (qRT-PCR)
assay targeting the EBOV NP gene was used for detec-
tion of EBOV and determination of viral load [18]. The
assay was run on a Stratagene MX300P real-time PCR
instrument and performed using the TaqMan Fast
Virus 1-Step Master Mix (Life Technologies) in
20 μL total reaction volume (5 μL 4× TaqMan mix,
1 μL sample extract), with 0.75 μM of each primer
(F565 5′-TCTGACATGGATTACCACAAGATC-3′, R640
Table 1 Flow cell run data
Exp/sample Flow
cell #




















Chik1 1 First run 345 138 19,452 5,139 14,313 35.9 % CHIKV 556 455 [126–1477] 20.6 % (8–49 %)
Ebola1 1 First run 105 1022 13,090 1,831 11,259 16.3 % EBOV 41 358 [220–672] 22.0 % (12–43 %)
HepC1 2 First run 171 122 10,305 729 9,877 7.4 % HCV 6 572 [318–792] 33.1 % (24–46 %)
HepC1 2 Reload #1 293 192 26,626 2,155 25,758 8.4 % HCV
HepC1 2 Reload #2 256 298 32,212 1,207 31,289 3.9 % HCV
HepC1 2 Reload #3 214 156 14,805 287 14,275 2.0 % HCV
Ebola2 3 First run 397 79 28,651 1,537 27,114 5.7 % EBOV 593 456 [189–1430] 22.3 % (8–48 %)
Ebola2 3 Reload #1 426 222 95,861 2,899 92,962 3.1 % EBOV
Ebola2 3 Reload #2 380 1091 166,524 1,539 164,985 0.9 % EBOV
Ebola2 3 Reload #3 200 1357 44,272 34 44,238 0.1 % EBOV
TOTAL 451,798 17,357 436,070 4.0 % 452 [126–1477] 24.3 % (8–49 %)
Expexperiment, CHIKV chikungunya virus, EBOV Ebola virus, HCV, hepatitis C virus
aBased on average pairwise identity of aligned viral reads to the most closely matched reference sequence
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5′-GGATGACTCTTTGCCGAACAATC-3′) and 0.6 μM
of the probe (p597S 6FAM-AGGTCTGTCCGTTCAA-
MGBNFQ). Conditions for the qRT-PCR were modified as
follows: 50 °C for 10 min and 95 °C for 20 s followed
by 45 cycles of 95 °C for 3 s plus 60 °C for 30 s. Viral
copy number was calculated by standard curve analysis
using a plasmid vector containing the EBOV amplicon.
The first EBOV sample analyzed by nanopore se-
quencing (Ebola1) corresponded to the Ebola virus/
H.sapiens-wt/COD/2014/Lomela-Lokolia16 strain, while
the second Ebola sample (Ebola2) corresponded to the
Ebola virus/H.sapiens-wt/COD/2014/Lomela-LokoliaB11
strain. The CHIKV-positive sample was identified and
quantified using a transcription-mediated amplification
assay (Hologic, Bedford, MA, USA) as previously de-
scribed [15]. HCV was quantified using the Abbott
RealTime RT-PCR assay, approved by the Food and Drug
Administration, as performed in the UCSF Clinical
Microbiology Laboratory on the Abbott Molecular
m2000 system.
Construction of metagenomic amplified cDNA libraries
To obtain ≥1 μg of metagenomic complementary DNA
(cDNA) for the library required for the nanopore
sequencing protocol, randomly amplified cDNA was
generated using a primer-extension pre-amplification
method (Round A/B) as described previously [19–21].
Of note, this protocol has been extensively tested on
clinical samples for metagenomic pan-pathogen detec-
tion of DNA and RNA viruses, bacteria, fungi, and
parasites [4, 6, 19, 21, 22]. Briefly, in Round A, RNA
was reverse-transcribed with SuperScript III Reverse
Transcriptase (Life Technologies,) using Sol-PrimerA
(5′-GTTTCCCACTGGAGGATA-N9-3′), followed by
second-strand DNA synthesis with Sequenase DNA
polymerase (Affymetrix, Santa Clara, CA, USA). Reaction
conditions for Round A were as follows: 1 μL of Sol-
PrimerA (40 pmol/μL) was added to 4 μL of sample
RNA, heated at 65 °C for 5 min, then cooled at room
temperature for 5 min. Then 5 μL of SuperScript Master
Mix (2 μl 5× First-Strand Buffer, 1 μL water, 1 μL
12.5 mM dNTP mix, 0.5 μL 0.1 M DTT, 0.5 μL SS III
RT) was added and incubated at 42 °C for 60 min. For
second strand synthesis, 5 μL of Sequenase Mix #1
(1 μL 5× Sequenase Buffer, 3.85 μL ddH2O, 0.15 μL
Sequenase enzyme) was added to the reaction mix
and incubated at 37 °C for 8 min, followed by addition of
Sequenase Mix #2 (0.45 μl Sequenase Dilution Buffer,
0.15 μl Sequenase Enzyme) and there was a second incu-
bation at 37 °C for 8 min. Round B reaction conditions
were as follows: 5 μL of Round A-labeled cDNA was
added to 45 μL of KlenTaq master mix per sample (5 μL
10× KlenTaq PCR buffer, 1 μL 12.5 mM dNTP, 1 μL
100 pmol/μL Sol-PrimerB (5′-GTTTCCCACTGGAG
GATA-3′), 1 μL KlenTaq LA (Sigma-Aldrich, St Louis,
MO), 37 μL ddH2O). Reaction conditions for the PCR
were as follows: 94 °C for 2 min; 25 cycles of 94 °C for
30 s, 50 °C for 45 s, and 72 °C for 60 s, followed by 72 °C
for 5 min.
Preparation of nanopore sequencing libraries
Amplified cDNA from Round B was purified using
AMPure XP beads (Beckman Coulter, Brea, CA), and
1 μg DNA was used as input into Oxford Nanopore
Genomic DNA MAP-003 Kits (Chik1, Ebola1) or MAP-
004 Kits (HepC1, Ebola2) for generation of MinION
Oxford Nanopore-compatible libraries [9, 11]. Briefly,
the steps include: (1) addition of control lambda phage
DNA, (2) end-repair with the NEBNext End Repair
Module, (3) 1× AMPure purification, (4) dA-tailing with
the NEBNext dA-tailing Module, (5) ligation to protein-
linked adapters HP/AMP (Oxford Nanopore Technologies,
Oxford, UK) using the NEBNext QuickLigation Module
for 10 min at room temperature, (6) purification of ligated
libraries using magnetic His-Tag Dynabeads (Life
Technologies), and (7) elution in 25 μL buffer (Oxford
Nanopore Technologies). Lambda phage DNA was not
added during preparation of the Ebola2 sample library.
Nanopore sequencing
Nanopore libraries were run on an Oxford Nanopore
MinION flow cell after loading 150 μL sequencing mix
(6 μL library, 3 μL fuel mix, 141 μL buffer) per the man-
ufacturer’s instructions. The Chik1 and Ebola1 samples
were run consecutively on the same flow cell, with an in-
terim wash performed using Wash-Kit-001 (Oxford
Nanopore).
Illumina sequencing
For the Chik1 and Ebola1 samples, amplified Round B
cDNA were purified using AMPure XP beads (Beckman
Coulter) and 2 ng used as input into the Nextera XT Kit
(Illumina). After 13 cycles of amplification, Illumina
library concentration and average fragment size were
determined using the Agilent Bioanalyzer. Sequencing
was performed on an Illumina MiSeq using 150 nu-
cleotide (nt) single-end runs and analyzed for viruses
using either the MetaPORE or SURPI computational
pipeline (UCSF) [19].
MetaPORE bioinformatics pipeline
We developed a custom bioinformatics pipeline for real-
time pathogen identification and visualization from
nanopore sequencing data (MetaPORE) (Fig. 1b), avail-
able under license from UCSF at [23]. The MetaPORE
pipeline consists of a set of Linux shell scripts, Python
programs, and JavaScript/HTML code, and was tested
and run on an Ubuntu 14.10 computational server with
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64 cores and 512 GB memory. In addition, MetaPORE
was tested and run on a laptop (Ubuntu 14.10, eight
hyper-threaded cores, 32 GB RAM). On the laptop,
to maximize sensitivity while still retaining the speed
necessary for real-time analysis and web-based
visualization, MetaPORE can either (1) restrict the
reference database for nucleotide BLAST (BLASTn)
alignment to viral sequences or (2) use the faster
MegaBLAST instead of the BLASTn algorithm at word
sizes ranging from 11 to 28 to align nanopore reads to all
of the National Center for Biotechnology Information
(NCBI) nucleotide collection database (NT database).
Running MegaBLAST to NT at a word size of 16
was found to detect ~85 % of nanopore CHIKV
reads (n = 196) with an ~8× speedup in processing
time relative to BLASTn, or 100 % of EBOV reads
(n = 98) with an ~5× speedup (Additional file 1:
Table S1). Overall, speeds of MegaBLAST to NT
alignment at a word size of 16 versus BLASTn to the viral
database were slower but comparable (Additional file 2:
Table S2).
Raw FAST5/HDF files from the MinION instrument
are base-called using the Metrichor 2D Basecalling v1.14
pipeline (Metrichor). The MetaPORE pipeline continu-
ally scans the Metrichor download directory for batch
analysis of downloaded sequence reads. For each batch
of files (collected every time 200 reads are downloaded
in the download directory, or ≥2 min of elapsed time,
whichever comes first), the 2D read or either the tem-
plate or complement read, depending on which is of
higher quality, is converted into a FASTQ file using
HDF5 Tools [24]. The cutadapt program is then used to
trim Sol-PrimerB adapter sequences from the ends of
the reads [25]. Next, the BLASTn aligner is used to sub-
tract host reads computationally [19, 26], aligning to the
human fraction of the NT database at word size 11 and
e-value cutoff of 10-5. The remaining, non-human reads
are then aligned by BLASTn (on a 64-core server) or
MegaBLAST (on a laptop) to the entire NT database,
using the same parameters. Alternatively, the remaining
reads can be aligned on a laptop using BLASTn to
just the viral fraction of the NT database, followed
by BLASTn alignment of the viral reads to the NT
database to verify that they are correctly identified.
For each read, the single best match by e-value is
retained, and the NCBI GenBank gene identifier
assigned to the best match is then annotated by
taxonomic lookup of the corresponding lineage, fam-
ily, genus, and species [19].
It has been reported that the LAST alignment algo-
rithm [27] may be more sensitive for nanopore read
identification [12, 28]. However, LAST was originally
developed for genome-scale alignments, and not for
huge databases such as the NT database. To date, it has
only been used to align nanopore reads to individual ref-
erence sequences [12, 28]. We attempted to use the
LAST software to align nanopore reads to the NT data-
base (June 2014, ~60 Gb in size). LAST automatically
created multiple formatted database volumes (n > 20),
each approximately 24 Gb, to encompass all of the NT
database. As the run time for loading each volume into
memory was just under 2 minutes, resulting in a >40 mi-
nutes overhead time, LAST was considered to be im-
practical for real-time metagenomic sequencing analysis
on a single server or laptop.
For real-time visualization of results, a graphical user
interface was developed for the MetaPORE pipeline. A
live taxonomic count table is displayed as a donut chart
using the CanvasJS graphics suite [29], with the chart
refreshing every 30 s (Additional file 3). For each viral
species detected, the top hit is chosen to be the refer-
ence sequence (GenBank identifier) in the NT database
assigned to that species with the highest number of
aligned reads, with priority given to reference se-
quences in the following order: (1) complete genomes,
(2) complete sequence, or (3) partial sequences or indi-
vidual genes. Coverage maps are generated by mapping
all aligned viral species reads to the top hit reference
sequence using LASTZ v1.02 [30], with interactive
visualization provided using a custom web program that
accesses the HighCharts JavaScript library [31]. A corre-
sponding interactive pairwise identity plot is generated
using SAMtools [32] to calculate the consensus FASTA
sequence from the coverage map, followed by pairwise
100-bp sliding-window comparisons of the consensus to
the reference sequence using the BioPython implementa-
tion of the Needleman–Wunsch algorithm [33, 34].
For comparison, the MetaPORE pipeline was also run
on a subset of 100,000 reads from parallel Illumina MiSeq
data corresponding to the Chik1, Ebola1, and Ebola2
samples.
Phylogenetic analysis
The overall CHIKV phylogeny consisted of all 188 near-
complete or complete genome CHIKV sequences
available in the NT database as of March 2015. A
subphylogeny, including the MiSeq- and nanopore-
sequenced Puerto Rico strain PR-S6 presented here and
previously [15], as well as additional Caribbean CHIKV
strains and other representative members of the Asian-
Pacific clade, was also analyzed. The EBOV phylogeny
consisted of the newly MiSeq- and nanopore-sequenced
Ebola strain Lomela-LokoliaB11 from the 2014 DRC
outbreak [17], as well as other representative EBOV
strains, including strains from the 2014–2015 West
African outbreak [8, 35]. Sequences were aligned using
the MAFFT algorithm [36], and phylogenetic trees were
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constructed using the MrBayes algorithm [37] in the
Geneious software package [38].
Data availability
Nanopore and MiSeq sequencing data corresponding
to non-human reads identified by MetaPORE, along
with sample metadata, have been submitted to NCBI
under the following GenBank Sequence Read Archive
(SRA) accession numbers: Ebola virus/H.sapiens-wt/
COD/2014/Lomela-Lokolia16 [SRA:SRP057409], Ebola
virus/H.sapiens-wt/COD/2014/Lomela-LokoliaB11 [SRA:
SRS933322], Chik1 [SRA:SRP057410] and HepC1
[SRA:SRP057418]. Sequence reads were additionally
filtered for exclusion of human sequences by both
BLASTn alignment at an e-value cutoff of 10-5 and
Bowtie2 high-sensitivity local alignment to the hu-
man hg38 reference database.
Results
Example 1: Nanopore sequencing of high-titer
chikungunya virus (Flow cell #1)
To test the ability of nanopore sequencing to identify
metagenomic reads from a clinical sample, we first ana-
lyzed a plasma sample harboring high-titer CHIKV and
previously sequenced on an Illumina MiSeq platform
(Fig. 2a) [15]. The plasma sample corresponded to an
asymptomatic blood donor who had screened positive
for CHIKV infection during the 2014 outbreak in Puerto
Rico (strain PR-S6), with a calculated viral titer of
9.1 × 107 copies/mL.
A read aligning to CHIKV, the 96th read, was se-
quenced within 6 min (Fig. 2b, left panel) and detected
by BLASTn alignment to the NT database within 8 min
of data acquisition, demonstrating an overall sample-to-
detection turnaround time of <6 hr (Fig. 1). After early
termination of the sequencing run at the 2 hr 15 min
time point, 556 of 19,452 total reads (2.8 %) were found
to align to CHIKV (Fig. 2b, c, left panels). The individual
CHIKV nanopore reads had an average length of 455 bp
(range 126–1477 bp) and average percentage identity of
79.4 % to the most closely matched reference strain, a
CHIKV strain from the neighboring British Virgin
Islands (KJ451624), corresponding to an average nano-
pore read error rate of 20.6 % (range 8–49 %) (Table 1).
When only high-quality 2D pass reads were included,
346 of 5139 (6.7 %) reads aligned to CHIKV, comparable
to the proportion of CHIKV reads identified by corre-
sponding metagenomic sequencing on the Illumina
MiSeq (7.6 % by MetaPORE analysis of 100,000 reads;
Fig. 3a, left panel).
Mapping of the 556 nanopore reads aligning to
CHIKV to the assigned reference genome (KJ451624)
showed recovery of 90 % of the genome at 3× coverage
and 98 % at 1× coverage (Fig. 2d, left panel). Notably,
despite high individual read error rates, 97–99 % identity
to the reference genome (KJ451624) was achieved across
contiguous regions with at least 3× coverage. Further-
more, phylogenetic analysis revealed co-clustering of the
CHIKV genomes independently assembled from MinION
nanopore or Illumina MiSeq reads (Fig. 2d, left panel and
Fig. 3b, left panel) on the same branch within the
Caribbean subclade (Fig. 2e). Overall, a large propor-
tion of reads (55 %) in the error-prone nanopore data
remained unidentifiable, while other aligning reads aside
from CHIKV corresponded to human, lambda phage
control spike-in, uncultured bacterial, or other eukaryotic
sequences (Fig. 2c, left panel).
Example 2: Nanopore sequencing of high-titer Ebola virus
(Flow cell #1)
We next attempted to replicate our metagenomic detec-
tion result on the nanopore sequencer with a different
virus by testing a whole blood sample from a patient
with Ebola hemorrhagic fever during the August 2014
outbreak in the DRC (Ebola1, strain Lomela-Lokolia16)
[17]. To conserve flow cells, the same nanopore flow cell
used to run the Chik1 sample was washed and stored
overnight at 4 °C, followed by nanopore sequencing of
the Ebola1 sample (viral titer of 1.0 × 107 copies/mL by
real-time qRT-PCR) (Fig. 2b, right panel). Only 41 of
13,090 nanopore reads (0.31 %) aligned to EBOV (Fig. 2c,
right panel), comparable to the percentage of reads ob-
tained for Illumina MiSeq (0.84 % by MetaPORE analysis
of 100,000 reads; Fig. 3a, right panel). The decrease in
relative number and percentage of target viral nanopore
reads in the Ebola1 sample relative to the Chik1 sample
is consistent with the lower levels of viremia (1.0 × 107
versus 9.1 × 107 copies/mL) and higher host background
(whole blood versus plasma). Nonetheless, the first read
aligning to EBOV was detected in a similar timeframe as
in the Chik1 sample, sequenced within 8 min and de-
tected within 10 min of data acquisition. EBOV nano-
pore reads were 359 bp in length on average (range
220–672 nt), with an average error rate of 22 % (range
12–43 %) (Table 1). However, despite these error rates,
the majority of Ebola nanopore sequences (31 of 41,
76 %) were found to align to the correct strain, Lomela-
Lokolia16, as confirmed by MiSeq sequencing (Fig. 2d,
right panel and Fig. 3b, right panel).
Despite washing the flow cell between the two succes-
sive runs, seven CHIKV reads were recovered during the
Ebola1 library sequencing, suggesting the potential for
carryover contamination. CHIKV reads were not present
in the corresponding Illumina MiSeq Ebola1 run (Fig. 3a,
right panel), confirming that the source of the contamin-
ation originated from the Chik1 nanopore library, which
was run on the same flow cell as and just prior to the
Ebola1 library.
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Fig. 2 Metagenomic identification of CHIKV and EBOV from clinical blood samples by nanopore sequencing. a Time line of sequencing runs on
flow cell #1 with sample reloading, plotted as a function of elapsed time in hours since the start of flow cell sequencing. b Cumulative numbers
of all sequenced reads (black line) and target viral reads (red line) from the Chik1 run (left panel) and Ebola1 run (right panel), plotted as a function
of individual sequencing run time in minutes. c Taxonomic donut charts generated using the MetaPORE bioinformatics analysis pipeline from the
Chik1 run (left panel) and Ebola1 run (right panel). The total number of reads analyzed is shown in the center of the donut. d Coverage plots
generated in MetaPORE by mapping reads aligning to CHIKV (left, Chik1 run) or EBOV (right, Ebola1 run) to the closest matching reference
genome ((e), asterisk). A corresponding pairwise identity plot is also shown for CHIKV, for which there is sufficient coverage. e Whole-genome
phylogeny of CHIKV. Representative CHIKV genome sequences from the Asian-Pacific clade, including the Puerto Rico PR-S6 strain recovered
by nanopore and MiSeq sequencing, or all available 188 near-complete or complete CHIKV genomes (inset), are included. Branch lengths are
drawn proportionally to the number of nucleotide substitutions per position, and support values are shown for each node. were was analyzed
in MetaPORE on a 64-core Ubuntu Linux server using the June 2014 and January 2015 NT databases as the reference databases for the CHIKV
and EBOV samples, respectively
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Example 3: Nanopore sequencing of moderate-titer
hepatitis C virus (Flow cell #2)
Our previous experiments revealed both the total num-
ber of metagenomic reads and proportion of target viral
reads at a given titer that could be obtained from a sin-
gle MinION flow cell, and showed that the proportion
of viral reads obtained by metagenomic nanopore and
MiSeq sequencing was comparable. Thus, we projected
that the minimum concentration of virus that could be
reproducibly detected using our current metagenomic
protocol would be 1 × 105 copies/mL. An HCV-positive
clinical sample (HepC1) was diluted in negative control
serum matrix to a titer of 1 × 105 copies/mL and proc-
essed for nanopore sequencing using an upgraded library
preparation kit (MAP-004). After four consecutive runs
on the same flow cell with repeat loading of the same
metagenomic HepC1 library (Fig. 4a), a total of 85,647
reads were generated, of which only six (0.0070 %)
aligned to HCV (Fig. 4b). Although the entire series of
flow cell runs lasted for >12 hr, the first HCV read was
sequenced within 34 min, enabling detection within
36 min of data acquisition. Given the low titer of HCV
in the HepC1 sample and hence low corresponding
fraction of HCV reads in the nanopore data, the vast
majority (96 %) of viral sequences identified corre-
sponded to the background lambda phage spike-in
(Fig. 4c). Importantly, although nanopore sequencing
identified only six HCV reads, all six reads aligned to
the correct genotype, genotype 1b (Fig. 4d).
Example 4: Nanopore sequencing of high-titer Ebola virus
with real-time MetaPORE analysis (Flow cell #3)
To enable real-time analysis of nanopore sequencing
data, we combined pathogen identification with moni-
toring and user-friendly web visualization into a real-
time bioinformatics pipeline named MetaPORE. We
tested MetaPORE by sequencing a nanopore library
(Ebola2) constructed using the upgraded MAP-004 kit
and corresponding to a whole blood sample from a pa-
tient with suspected Ebola hemorrhagic fever during the
2014 DRC outbreak. Four consecutive runs of the Ebola2
library on the same flow cell over 34 hr (Fig. 5a) yielded
a total of 335,308 reads, of which 609 (0.18 %) aligned to
EBOV (141 of 6009 or 2.3 %, of 2D pass reads), compar-
able to the 0.91 % achieved by Illumina MiSeq sequen-
cing (Fig. 5c).
Chikungunya virus (gi|615794507|, 12011 bp)
Chikungunya virus strain 99659, complete genome
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Fig. 3 MetaPORE analysis of Illumina MiSeq data from samples containing CHIKV and EBOV. Taxonomic donut charts were generated from
Illumina MiSeq data corresponding to the Chik1 run (a) and Ebola1 run (b) using the MetaPORE bioinformatics analysis pipeline. The total
number of MiSeq reads analyzed is shown in the center of the donut. Note that given computational time constraints, only a subset of reads (n
= 100,000) was analyzed using MetaPORE. Coverage and pairwise identity plots were generated from MiSeq CHIKV reads from the Chik1 sample
(248,677 of 3,235,099 reads, 7.7 %) (c), or EBOV reads from the Ebola1 sample (20,820 of 2,743,589 reads, 0.76 %) (d), identified using SURPI
analysis and LASTZ mapping {Harris, 2007 #34} at an e-value of 10-5 to the closest matching reference genome. Data were analyzed in MetaPORE
on a 64-core Ubuntu Linux server using the June 2014 and January 2015 NT databases as the reference databases for the CHIKV and EBOV
samples, respectively.
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Notably, the first EBOV read was sequenced 44 s after
data acquisition and correctly detected in ~3 min by
MetaPORE (Fig. 5b, right panel; Additional file 3). The
mapping of nanopore reads across the EBOV genome
was relatively uniform with at least one read map-
ping to >88 % of the genome and areas of zero
coverage also seen with much higher-coverage Illu-
mina MiSeq data (Fig. 5d). The detection of EBOV
by real-time metagenomic nanopore sequencing was
confirmed by qRT-PCR testing of the clinical blood
sample, which was positive for EBOV at an estimated
titer of 7.64 × 107 copies/mL. Phylogenetic analysis of
the Ebola2 genome independently recovered by MinION
nanopore and Illumina MiSeq sequencing revealed that
nanopore sequencing alone was capable of pinpointing
the correct EBOV outbreak strain and country of origin
(Fig. 5e).
Discussion
Unbiased point-of-care testing for pathogens by rapid
metagenomic sequencing has the potential to transform
radically infectious disease diagnosis in clinical and pub-
lic health settings. In this study, we sought to demon-
strate the potential of the nanopore instrument for
metagenomic pathogen identification in clinical samples
by coupling an established assay protocol with a new
real-time sequence analysis pipeline. To date, high re-
ported error rates (10–30 %) and relatively low through-
put (<100,000 reads per flow cell) have hindered the
utility of nanopore sequencing for analysis of metage-
nomic clinical samples [9, 11]. Prior work on infectious
disease diagnostics using nanopore has focused on rapid
PCR amplicon sequencing of viruses and bacteria [11],
or real-time sequencing of pure bacterial isolates in cul-
ture, such as Salmonella in a hospital outbreak [12]. To
our knowledge, this is the first time that nanopore
sequencing has been used for real-time metagenomic de-
tection of pathogens in complex, high-background clin-
ical samples in the setting of human infections. Here, we
also sequenced a near-complete viral genome to high ac-
curacy (97–99 % identity) directly from a primary clin-
ical sample and not from culture. As also demonstrated
previously for the bacterium Escherichia coli K-12 [13],
the CHIKV genome was assembled using only multiple
overlapping, albeit error-prone, nanopore reads and
without resorting to the use of a secondary platform
such as an Illumina MiSeq for sequence correction
(Fig. 2d).
Real-time sequence analysis is necessary for time-
critical applications such as outbreak investigation [7]
and metagenomic diagnosis of life-threatening infections
in hospitalized patients [3, 4, 6]. NGS analysis for clinical
BA
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Fig. 4 Metagenomic identification of HCV from a clinical serum sample by nanopore sequencing. a Time line of sequencing runs on flow cell #2
with HepC1 sample reloading, plotted as a function of elapsed time in hours since the start of flow cell sequencing. b Cumulative number of all
sequenced reads (black line) and HCV viral reads (red line), plotted as a function of individual sequencing run time in minutes. c Taxonomic donut
charts generated using the MetaPORE bioinformatics analysis pipeline. The total number of reads analyzed is shown in the center of the donut.
d Coverage and pairwise identity plots generated in MetaPORE by mapping reads aligning to HCV to the closest matching reference genome.
Data were analyzed in MetaPORE on a 64-core Ubuntu Linux server using the January 2015 NT reference database
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Zaire ebolavirus isolate
Ebola virus/H.sapiens-wt/COD/2014/Lomela-Lokolia16, complete genome
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Fig. 5 Metagenomic identification of EBOV from a clinical blood sample by nanopore sequencing and MetaPORE real-time bioinformatics analysis.
Nanopore data generated from the Ebola2 library and sequenced on flow cell #3 were analyzed in real time using the MetaPORE bioinformatics
analysis pipeline, and compared to corresponding Illumina MiSeq data. a Time line of nanopore sequencing runs on flow cell #3 with sample
reloading, plotted as a function of elapsed time in hours since the start of flow cell sequencing. b Cumulative numbers of all sequenced reads (black
line) and target viral reads (red line) from the nanopore run (left panel) or MiSeq run (right panel), plotted as a function of individual sequencing run
time in minutes. c Taxonomic donut charts generated by real-time MetaPORE analysis of the nanopore reads (left panel) and post-run analysis of the
MiSeq reads (right panel). The total number of reads analyzed is shown in the center of the donut. Note that given computational time constraints,
only a subset of MiSeq reads (n = 100,000) was analyzed using MetaPORE. d Coverage and pairwise identity plots generated from nanopore (left
panel) or MiSeq data (right panel) by mapping reads aligning to EBOV to the closest matching reference genome ((e), asterisk). e Whole-genome
phylogeny of EBOV. Representative EBOV genome sequences, including those from the 2014-2015 West Africa outbreak (tan) and 2014 DRC outbreak
(pink), are included. Branch lengths are drawn proportionally to the number of nucleotide substitutions per position, and support values are shown for
each node. Data were analyzed in MetaPORE on a 64-core Ubuntu Linux server using the January 2015 NT reference database.
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diagnostics is currently performed after sequencing is
completed, analogous to how PCR products were ana-
lyzed by agarose gel electrophoresis in the 1990s. Most
clinical PCR assays to date have since been converted to
a real-time format that reduces hands-on laboratory
technician time and effort and decreases overall sample-
to-answer turnaround times. Importantly, our nanopore
data suggest that very few reads are needed to provide
an unambiguous diagnostic identification, despite high
individual per read error rates of 10–30 %. The ability of
nanopore sequence analysis to identify viruses accurately
to the species and even strain or genotype level is facili-
tated by the high specificity of viral sequence data, espe-
cially with the longer reads achievable by nanopore
versus second-generation sequencing (Table 1, 452 bp;
range 126–1477 bp).
Although the overall turnaround time for metagenomic
sample-to-detection has now been reduced to <6 hr with
nanopore sequencing, many challenges remain for rou-
tine implementation of this technology in clinical and
public health settings. Improvements to make library
preparation faster and more robust are critical, including
automation and optimization of each step in the proto-
col. Standardized external and internal spike-in controls
run in parallel will be needed to control for labora-
tory and carryover contamination. Here we looked
only at clinical samples at moderate to high titers of
105–108 copies/mL, and the sensitivity of metagenomic
nanopore sequencing at lower titers remains unclear at
current achievable sequencing depths. Standard wash
protocols also appear inadequate to prevent carryover
contamination when reusing the same flow cell, as
CHIKV reads were identified in the downstream Ebola1
sample sequence run. One solution may be to perform
only one nanopore sequencing run per flow cell for clin-
ical diagnostic purposes, akin to how individual dispos-
able cartridges are used for clinical quantitative PCR
testing on a Cepheid GenXpert instrument to prevent
cross-contamination [39]. Another potential solution is
to give unique barcodes to individual samples as part of a
multiplexed sequencing run at the cost of added time
and effort.
A key challenge with microbial identification by meta-
genomic nanopore sequencing is that the current accur-
acy of sparse nanopore reads is insufficient to allow
confident species identification of bacteria, fungi, or par-
asites, which have much larger genomes and share more
conserved genes than viruses. Indeed, distinct bacterial
species are often defined by as little as 5 % genomic di-
vergence and 1 % sequence divergence in highly con-
served housekeeping genes such as 16S ribosomal RNA
[40]. Of note, the majority of nanopore reads aligning to
bacteria in this study likely originated from the inclusion
of lambda phage DNA in the sequencing library, reagent
contamination, or, for the Ebola virus samples, environ-
mental contamination from sample collection in a rural
hospital setting (Additional file 4: Table S3). Accurate
identification of eukaryotic pathogens from sparse,
error-prone nanopore reads also appears to be challen-
ging (Additional file 4: Table S3). In addition, single-
nucleotide resolution will likely be required for detection
of antimicrobial resistance markers [41], which is difficult
to achieve from relatively low-coverage metagenomic data
[42]. These limitations can potentially be overcome in the
future by target enrichment methods such as capture
probes to increase coverage, improvements in nanopore
sequencing technology, or more accurate base-calling and
alignment algorithms for nanopore data [43, 44].
Conclusions
Our results indicate that unbiased metagenomic detec-
tion of viral pathogens from clinical samples with a
sample-to-answer turnaround time of <6 hr and real-
time bioinformatics analysis is feasible with nanopore
sequencing. We demonstrate unbiased, diagnostic iden-
tification of EBOV within ~3 min of sequence acquisi-
tion. This technology will be particularly desirable for
enabling point-of-care genomic analyses in the develop-
ing world, where critical resources, including reliable
electric power, laboratory space, and computational ser-
ver capacity, are often severely limited. Importantly,
MetaPORE, the real-time sequencing analysis platform
developed here, is web-based and can be run on a lap-
top. As sequencing yield, quality, and turnaround times
continue to improve, we anticipate that third-generation
technologies such as nanopore sequencing will chal-
lenge clinical diagnostic mainstays such as PCR and
transcription-mediated amplification testing, fulfilling
the dream of an unbiased, point-of-care test for infectious
diseases.
Additional files
Additional file 1: Table S1. Optimization of word count for MegaBLAST
alignment to the NT reference database. (XLSX 12 kb)
Additional file 2: Table S2. MetaPORE performance according to
system configuration and alignment mode. (XLSX 18 kb)
Additional file 3: Movie. MetaPORE real-time bioinformatics analysis and
visualization (clip 0:19–10:13, 9.8 min). Detection of EBOV by metagenomic
nanopore sequencing and real-time MetaPORE bioinformatics analysis. Raw
FAST5 files are uploaded to the Metrichor cloud-based analytics platform for
2D base-calling (clip, right panel). After downloading from Metrichor,
base-called FAST5 reads are collected in batches of 200 reads and
automatically processed in real time by MetaPORE. Read counts corresponding
to detected organisms (e.g. humans, viruses, bacteria, non-human eukaryotes)
and viral species are displayed in donut plots that are updated each
minute in real time (left panel). Note that the first EBOV read from the
Ebola2 sequencing run is detected 3 min 6 s (3:26) after the start of
sequence acquisition (0:19). (clip 10:21–11:51, 1.5 min). Web-based,
interactive coverage map and pairwise identity plots, generated in real
time by MetaPORE, enable zooming, highlighting of individual values,
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outputting of relevant statistical data, and exporting of the graphs in
various formats. The plots shown in the movie correspond to the analyzed
data after completion of nanopore sequencing. Data were analyzed in
MetaPORE on a 64-core Ubuntu Linux server using the January 2015 NT
reference database. (MP4 20493 kb)
Additional file 4: Table S3. Taxonomic classification of non-human
nanopore reads identified using MetaPORE. (XLSX 117 kb)
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